Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical family donor stem cell transplantation for hematological malignancies
ACTRN12613000338763Phase 2Completed
- Sponsor
- St Vincent's Hospital
- Start
- May 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of peripheral blood stem cells, cytarabine, busulfan, cyclophosphamide, lomustine and 5 more in hematopoietic malignancies (2 arms), sponsored by St Vincent's Hospital. Primary endpoints: Leukemia-free survival and Overall survival. Started May 2009; status: completed.
02
Drugs
peripheral blood stem cellscytarabinebusulfancyclophosphamidelomustine
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on ACTRN12613000338763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000338763.